Cell Reports (Dec 2019)

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer

  • Deepak Parashar,
  • Anjali Geethadevi,
  • Miriam Ragle Aure,
  • Jyotsna Mishra,
  • Jasmine George,
  • Changliang Chen,
  • Manoj K. Mishra,
  • Andliena Tahiri,
  • Wei Zhao,
  • Bindu Nair,
  • Yiling Lu,
  • Lingegowda S. Mangala,
  • Cristian Rodriguez-Aguayo,
  • Gabriel Lopez-Berestein,
  • Amadou K.S. Camara,
  • Mingyu Liang,
  • Janet S. Rader,
  • Ramani Ramchandran,
  • Ming You,
  • Anil K. Sood,
  • Vessela N. Kristensen,
  • Gordon B. Mills,
  • Sunila Pradeep,
  • Pradeep Chaluvally-Raghavan

Journal volume & issue
Vol. 29, no. 13
pp. 4389 – 4406.e10

Abstract

Read online

Summary: Genomic amplification of 3q26.2 locus leads to the increased expression of microRNA 551b-3p (miR551b-3p) in triple-negative breast cancer (TNBC). Our results demonstrate that miR551b-3p translocates to the nucleus with the aid of importin-8 (IPO8) and activates STAT3 transcription. As a consequence, miR551b upregulates the expression of oncostatin M receptor (OSMR) and interleukin-31 receptor-α (IL-31RA) as well as their ligands OSM and IL-31 through STAT3 transcription. We defined this set of genes induced by miR551b-3p as the “oncostatin signaling module,” which provides oncogenic addictions in cancer cells. Notably, OSM is highly expressed in TNBC, and the elevated expression of OSM associates with poor outcome in estrogen-receptor-negative breast cancer patients. Conversely, targeting miR551b with anti-miR551b-3p reduced the expression of the OSM signaling module and reduced tumor growth, as well as migration and invasion of breast cancer cells. : Parashar et al. demonstrate that the mature microRNA-551b-3p translocates to the nucleus for transcriptional activation of STAT3 gene. As a consequence, miR551b activates an autocrine signaling loop through the upregulation of oncostatin family genes, including oncostatin, and its receptors for the growth and metastasis of triple-negative breast cancer. Keywords: miR551b, oncostatin, STAT3, OSMR, miRNA-therapy, IPO8, RNAi